Ancestry.com takes DNA ownership rights from customers and their relatives
By Joel Winston,
Medium
| 05. 17. 2017
A word to the wise: Read the complete terms of service.
Don’t use the AncestryDNA testing service without actually reading the Ancestry.com Terms of Service and Privacy Policy. According to these legal contracts, you still own your DNA, but so does Ancestry.com.
The family history website Ancestry.com is selling a new DNA testing service called AncestryDNA. But the DNA and genetic data that Ancestry.com collects may be used against “you or a genetic relative.” According to its privacy policies, Ancestry.com takes ownership of your DNA forever. Your ownership of your DNA, on the other hand, is limited in years.
It seems obvious that customers agree to this arrangement, since all of them must “click here to agree” to these terms. But, how many people really read those contacts before clicking to agree? And how many relatives of Ancestry.com customers are also reading?
There are three significant provisions in the AncestryDNA Privacy Policy and Terms of Service to consider on behalf of yourself and your genetic relatives: (1) the perpetual, royalty-free, world-wide license to use your DNA; (2) the warning that DNA...
Related Articles
By Jim Thomas, Scan the Horizon | 11.19.2024
It’s the wee hours of 2nd November 2024 in Cali, Colombia. In a large UN negotiating hall Colombian Environment Minister Susana Muhamed has slammed down the gavel on a decision that should send a jolt through the AI policy world. ...
By Ewan Bolton, The Telegraph | 11.12.2024
Fertility agencies offering embryo selection for IVF and surrogacy have been accused of promoting eugenics and misleading consumers about the power of genetic screening.
Some American clinics claim they can “rank” embryos for IVF using Preimplantation Genetic Testing for Polygenic...
By Ned Pagliarulo, BioPharmaDive | 11.05.2024
A medicine built around a more precise form of CRISPR gene editing appeared to work as designed in its first clinical trial test, developer Beam Therapeutics said Tuesday. But the death of a trial participant could renew concerns about an older...
By Fyodor Urnov, The CRIPSR Journal | 10.18.2024
The field of clinical gene editing has a bona fide crisis on its hands—a crisis that has to, and can be, promptly resolved.
An outside observer of our field might be surprised by this and say—what crisis? The first...